Genetic variation in COMT and PRODH is associated with brain anatomy in patients with schizophrenia

Haploinsufficiency of 22q11 genes including catechol‐O‐methyltransferase (COMT) and proline dehydrogenase (PRODH) may result in structural and functional brain abnormalities and increased vulnerability to schizophrenia as observed in patients with microdeletions of 22q11. Thus, COMT and PRODH could be modifier genes for schizophrenia. We examined association of polymorphisms in COMT and PRODH with brain anatomy in young patients with schizophrenia and schizoaffective disorder. We acquired structural magnetic resonance imaging data from 51 male patients and genotyped two single nucleotide polymorphisms (SNPs) in the COMT gene and three in the PRODH gene. Statistical Parametric Mapping software and optimized voxel‐based morphometry were used to determine regional gray matter (GM) and white matter (WM) density differences, and total GM and WM volume differences between genotype groups. Two nonsynonymous SNPs in the PRODH gene were associated with bilateral frontal WM density reductions and an SNP in the P2 promoter region of COMT (rs2097603) was associated with GM increase in the right superior temporal gyrus. Furthermore, we found evidence for COMT and PRODH epistasis: in patients with a COMT Val allele (rs4680) and with one or two mutated PRODH alleles, we observed increased WM density in the left inferior frontal lobe. Our results suggest that genetic variation in COMT and PRODH has significant effects on brain regions known to be affected in schizophrenia. Further research is needed to investigate the role of 22q11 genes on brain structure and function and their role in vulnerability for schizophrenia.

[1]  Karl J. Friston,et al.  Unified segmentation , 2005, NeuroImage.

[2]  David J Mikulis,et al.  Structural brain abnormalities in patients with schizophrenia and 22q11 deletion syndrome , 2002, Biological Psychiatry.

[3]  R. Nussbaum,et al.  Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype , 2005, Nature Neuroscience.

[4]  T. Crow,et al.  Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. , 2005, The American journal of psychiatry.

[5]  M. Egan,et al.  Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. , 2004, American journal of human genetics.

[6]  Ellen M Wijsman,et al.  Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[7]  R. Straub,et al.  Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Hidehiro Iida,et al.  The association between the Val158Met polymorphism of the catechol-O-methyl transferase gene and morphological abnormalities of the brain in chronic schizophrenia. , 2006, Brain : a journal of neurology.

[9]  Xu-Feng Huang,et al.  Early brain development disruption from NMDA receptor hypofunction: Relevance to schizophrenia , 2007, Brain Research Reviews.

[10]  M. Egan,et al.  Prefrontal neurons and the genetics of schizophrenia , 2001, Biological Psychiatry.

[11]  R. Gibbs,et al.  Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Lieberman,et al.  A comprehensive analysis of 22q11 gene expression in the developing and adult brain , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[13]  R. McCarley,et al.  A review of MRI findings in schizophrenia , 2001, Schizophrenia Research.

[14]  Jie Qin,et al.  Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice , 2005, Nature Neuroscience.

[15]  J. Lauriello,et al.  Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. , 2005, The American journal of psychiatry.

[16]  G. Kirov,et al.  Association between PRODH and schizophrenia is not confirmed , 2003, Molecular Psychiatry.

[17]  Stephan Eliez,et al.  COMT genotype predicts longitudinal cognitive decline and psychosis in 22q11.2 deletion syndrome , 2005, Nature Neuroscience.

[18]  M. Owen,et al.  Cognitive deficits associated with schizophrenia in velo-cardio-facial syndrome , 2004, Schizophrenia Research.

[19]  D. Campion,et al.  PRODH mutations and hyperprolinemia in a subset of schizophrenic patients. , 2002, Human molecular genetics.

[20]  Karl J. Friston,et al.  Voxel-Based Morphometry—The Methods , 2000, NeuroImage.

[21]  S. Almashanu,et al.  Functional consequences of PRODH missense mutations. , 2005, American journal of human genetics.

[22]  High Rates of Schizophrenia in Adults With Velo-Cardio-Facial Syndrome , 1999 .

[23]  Paul J. Harrison,et al.  Catechol-o-Methyltransferase, Cognition, and Psychosis: Val158Met and Beyond , 2006, Biological Psychiatry.

[24]  J Ashburner,et al.  Computational neuroanatomy: new perspectives for neuroradiology. , 2001, Revue neurologique.

[25]  Alan C. Evans,et al.  Genetic Contributions to Human Brain Morphology and Intelligence , 2006, The Journal of Neuroscience.

[26]  T. Sigmundsson,et al.  Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms. , 2001, The American journal of psychiatry.

[27]  M. Torrens.  Co-Planar Stereotaxic Atlas of the Human Brain—3-Dimensional Proportional System: An Approach to Cerebral Imaging, J. Talairach, P. Tournoux. Georg Thieme Verlag, New York (1988), 122 pp., 130 figs. DM 268 , 1990 .

[28]  D. Skuse,et al.  COMT Val108/158Met Modifies Mismatch Negativity and Cognitive Function in 22q11 Deletion Syndrome , 2005, Biological Psychiatry.

[29]  G. Kirov,et al.  Detailed analysis of PRODH and PsPRODH reveals no association with schizophrenia , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[30]  M. Karayiorgou,et al.  The gene encoding proline dehydrogenase modulates sensorimotor gating in mice , 1999, Nature Genetics.

[31]  B. Turetsky,et al.  Reduced dorsal and orbital prefrontal gray matter volumes in schizophrenia. , 2000, Archives of general psychiatry.

[32]  F. Baas,et al.  The COMT val 158 met polymorphism and brain morphometry in healthy young adults , 2006, Neuroscience Letters.

[33]  J. Werker,et al.  Do you hear what I hear? Neural correlates of thought disorder during listening to speech in schizophrenia , 2006, Schizophrenia Research.

[34]  K. Dikranian,et al.  Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity , 2002, Molecular Psychiatry.

[35]  Thomas E. Nichols,et al.  Impact of complex genetic variation in COMT on human brain function , 2006, Molecular Psychiatry.

[36]  M. Munafo,et al.  Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: a meta-analysis of case–control studies , 2005, Molecular Psychiatry.

[37]  M. Wong,et al.  150 years of Sigmund Freud: what would Freud have said about the obesity epidemic? , 2006, Molecular Psychiatry.

[38]  Ravi S. Menon,et al.  Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. , 2003, The American journal of psychiatry.

[39]  J Suckling,et al.  Structural brain abnormalities associated with deletion at chromosome 22q11 , 2001, British Journal of Psychiatry.

[40]  I. Johnsrude,et al.  The problem of functional localization in the human brain , 2002, Nature Reviews Neuroscience.

[41]  A. Chakravarti.  A compelling genetic hypothesis for a complex disease: PRODH2/DGCR6 variation leads to schizophrenia susceptibility , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[42]  K K Kidd,et al.  COMT haplotypes suggest P2 promoter region relevance for schizophrenia , 2004, Molecular Psychiatry.

[43]  Dennis Velakoulis,et al.  Neuropathological, neurogenetic and neuroimaging evidence for white matter pathology in schizophrenia , 2006, Neuroscience & Biobehavioral Reviews.

[44]  D. Linszen,et al.  Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. , 2002, The Journal of clinical psychiatry.

[45]  T. van Amelsvoort,et al.  Chromosome 22q11 deletion and brain tissue composition , 2001, British Journal of Psychiatry.

[46]  N C Andreasen,et al.  Catechol-O-methyl transferase Val158Met gene polymorphism in schizophrenia: working memory, frontal lobe MRI morphology and frontal cerebral blood flow , 2005, Molecular Psychiatry.

[47]  D. Goff,et al.  Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia , 2003, Annals of the New York Academy of Sciences.

[48]  Paul J. Harrison,et al.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence , 2005, Molecular Psychiatry.

[49]  Eileen Daly,et al.  Brain anatomy in adults with velocardiofacial syndrome with and without schizophrenia: preliminary results of a structural magnetic resonance imaging study. , 2004, Archives of general psychiatry.

[50]  S Eliez,et al.  Children and adolescents with velocardiofacial syndrome: a volumetric MRI study. , 2000, The American journal of psychiatry.

[51]  Eileen Daly,et al.  Processing facial emotions in adults with velo-cardio-facial syndrome: functional magnetic resonance imaging , 2006, British Journal of Psychiatry.

[52]  G. Kirov,et al.  No association between schizophrenia and polymorphisms in COMT in two large samples. , 2005, The American journal of psychiatry.

[53]  I. Gut,et al.  Genotyping single-nucleotide polymorphisms by matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[54]  A. Nieoullon.  Dopamine and the regulation of cognition and attention , 2002, Progress in Neurobiology.

[55]  Philip D. Harvey,et al.  White matter changes in schizophrenia: evidence for myelin-related dysfunction. , 2003, Archives of general psychiatry.

[56]  R. McCarley,et al.  MRI anatomy of schizophrenia , 1999, Biological Psychiatry.

[57]  Lin He,et al.  Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: A large-scale association study plus meta-analysis , 2005, Biological Psychiatry.

[58]  D. Skuse,et al.  COMT Val108/158 Met modifies mismatch negativity and cognitive function in 22q11 deletion syndrome. , 2005, Biological psychiatry.

[59]  Ravi S. Menon,et al.  Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. , 2002, The American journal of psychiatry.

[60]  R. Murray,et al.  Evidence for association between novel polymorphisms in the PRODH gene and schizophrenia in a Chinese population , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[61]  D. Campion,et al.  Hyperprolinemia is a risk factor for schizoaffective disorder , 2005, Molecular Psychiatry.

[62]  Godfrey D Pearlson,et al.  Regional cortical white matter reductions in velocardiofacial syndrome: a volumetric MRI analysis , 2001, Biological Psychiatry.

[63]  N. Volkow,et al.  Glutamate Modulation of Dopamine Measured in Vivo with Positron Emission Tomography (PET) and 11C-Raclopride in Normal Human Subjects , 1998, Neuropsychopharmacology.

[64]  S. Lawrie,et al.  Brain structure, genetic liability, and psychotic symptoms in subjects at high risk of developing schizophrenia , 2001, Biological Psychiatry.

[65]  J. Coyle,et al.  The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. , 2001, The American journal of psychiatry.

[66]  S. Ho,et al.  Human catechol-O-methyltransferase down-regulation by estradiol , 2003, Neuropharmacology.

[67]  J. Coyle,et al.  A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. , 1999, Archives of general psychiatry.

[68]  Tyrone D. Cannon,et al.  Cortex mapping reveals regionally specific patterns of genetic and disease-specific gray-matter deficits in twins discordant for schizophrenia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[69]  T. van Amelsvoort,et al.  Involvement of hyperprolinemia in cognitive and psychiatric features of the 22q11 deletion syndrome. , 2007, Human molecular genetics.